Meeting
2023 ASCO Annual Meeting
Revisiting the optimal neoadjuvant immunotherapy regimen in resectable stage III melanoma based on the interferon gamma signature: A pooled analysis.
Authors
Minke W. Lucas
Netherlands Cancer Institute, Amsterdam, Netherlands
Minke W. Lucas , Petros Dimitriadis , Irene L.M. Reijers , Alexander M. Menzies , Elisa A. Rozeman , Judith M. Versluis , Alexander Chan Chi Huang , Sten Cornelissen , Annegien Broeks , Richard A. Scolyer , Tara C. Mitchell , Georgina V. Long , Christian U. Blank
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Local-Regional Disease
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9516)
DOI
10.1200/JCO.2023.41.16_suppl.9516
Abstract #
9516
Poster Bd #
279
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
The interferon-gamma (IFN-y) signature from baseline tumor material predicts pathologic response after neoadjuvant ipilimumab (IPI) + nivolumab (NIVO) in stage III melanoma.
First Author: Irene L.M. Reijers
Poster
2022 ASCO Annual Meeting
The NADINA trial: A multicenter, randomised, phase 3 trial comparing the efficacy of neoadjuvant ipilimumab plus nivolumab with standard adjuvant nivolumab in macroscopic resectable stage III melanoma.
First Author: Minke W. Lucas
Poster
2020 ASCO Virtual Scientific Program
Personalized combination of neoadjuvant domatinostat, nivolumab and ipilimumab in macroscopic stage III melanoma patients stratified according to the interferon-gamma signature: The DONIMI study.
First Author: Irene L.M. Reijers
Poster
2022 ASCO Annual Meeting
Survival update of neoadjuvant ipilimumab + nivolumab in macroscopic stage III melanoma: The OpACIN and OpACIN-neo trials.
First Author: Judith M. Versluis